Inflammatory breast cancer: An atypical breast cancer type

IBC diagnosis is still based on visible symptoms rather than a specific pathological test.
IBC diagnosis is still based on visible symptoms rather than a specific pathological test.

To start this activity click Next at the bottom of this page

Release date: June 30, 2015

Expiration date: June 30, 2016

STATEMENT OF NEED/PROGRAM OVERVIEW

Inflammatory breast cancer (IBC) is a less common and aggressive form of breast cancer. Early recognition of its signs and symptoms can lead to an accurate diagnosis and timely initiation of treatment. This activity provides an overview of the signs of IBC, its multimodal treatment regimen, and the unique challenges of managing the care of patients with IBC.

EDUCATIONAL OBJECTIVES

After participating in this activity, clinicians should be better able to

• Identify the key clinical signs and symptoms of inflammatory breast cancer (IBC)

• Describe the sequence of multimodal therapy for newly diagnosed inflammatory breast cancer

• List the longstanding effects of IBC treatment on patients and their caregivers

FACULTY

Virginia Mason, RN, BSN
Executive Director, Inflammatory Breast Cancer Research Foundation
West Lafayette, Indiana

Beth Overmoyer, MD
Director, Inflammatory Breast Cancer Program at Dana-Farber Cancer Institute
Boston, Massachusetts

LEARNING GOALS/PURPOSE

To know the signs and symptoms, diagnostic process, and treatment options for this less common but aggressive form of breast cancer.

NURSING CREDIT

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity is designated for 0.25 ANCC pharmacotherapeutic contact hours. This CE activity provides 1 contact hour of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1 contact hour.

METHOD OF PARTICIPATION

There are no fees for participating in and receiving credit for this activity. During the period June 2015 through June 2016, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by selecting the best answer to each question on the posttest, 4) complete the evaluation form, and 5) continue to next section to claim credits and view your certificate.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Statements of credit are available at the conclusion of the activity.

MEDIA

Journal article and Web site (myCME.com; OncologyNurseAdvisor.com)

Disclosure of Conflicts of Interest

Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name of faculty: Virginia Mason, RN, BSN and Beth Overmoyer, MD

Reported Financial Relationship: No financial relationships to disclose

The content managers  reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name of Content Manager and Reported Financial Relationship

Joyce Pagán (No financial relationships to disclose)

Planners and Manager from MER (No financial relationships to disclose)

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources or Haymarket Medical.  The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medical Education Resources or Haymarket Medical.  Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

NEXT


HOW TO TAKE THE POST-TEST: To obtain CE credit, please click here after reading the article to take the post-test on myCME.com.


Page 1 of 4
Loading links....
You must be a registered member of ONA to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs